Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stimcell EnergeticsSTME 26 Equity-to-Asset is -47.94 as of Feb. 2026. GuruFocus rates STME with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Stimcell Energetics ranks worse than 99.88% on this metric.
The historical rank and industry rank for Stimcell Energetics's Equity-to-Asset or its related term are showing as below:
STME'
s Equity-to-Asset Range Over the Past 10 Years
Min: -164.64 Med: -18.43 Max: -1.33
Current: -47.94
During the past 13 years, the highest Equity to Asset Ratio of Stimcell Energetics was -1.33. The lowest was -164.64. And the median was -18.43.
STME's Equity-to-Asset is ranked worse than 99.88% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs STME: -47.94
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Stimcell Energetics Equity-to-Asset Related Terms
Stimcell Energetics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Stimcell Energetics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STME vs TRIB, AIDX, VVOS: Equity-to-Asset Comparison
For the Medical Devices subindustry, Stimcell Energetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stimcell Energetics Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stimcell Energetics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Stimcell Energetics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Stimcell Energetics's Equity to Asset Ratio for the fiscal year that ended in May. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stimcell Energetics (STME) has a Equity-to-Asset of -47.94 as of Feb. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Stimcell Energetics and its competitors. According to the industry distribution chart, Stimcell Energetics ranks #852 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 99.9%.
Is Stimcell Energetics' Equity-to-Asset too high?
Stimcell Energetics' current Equity-to-Asset is -47.94. Based on the distribution chart, Stimcell Energetics ranks #852 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stimcell Energetics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Stimcell Energetics' Equity-to-Asset compare to TRIB and AIDX?
According to the Medical Devices & Instruments industry distribution chart, Stimcell Energetics ranks #852 out of 853 companies for Equity-to-Asset. This places Stimcell Energetics in the lower half of its industry. The industry median Equity-to-Asset is 0.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Stimcell Energetics and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stimcell Energetics's current Equity-to-Asset is -47.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stimcell Energetics stock overvalued right now?
Stimcell Energetics (STME) has a current Equity-to-Asset of -47.94. The current Equity-to-Asset is -47.94. Stimcell Energetics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Stimcell Energetics (STME), the current Equity-to-Asset is -47.94 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stimcell Energetics Inc is a biotech company focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness, and alleviate health complications, including, but not limited to: aging, diabetes, high blood pressure, neuropathy, and kidney function. The company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.
26GF Score
Get the complete analysis for STME
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STME has been successfully added to your 
